TW202313630A - 含氮雜環類化合物、其製備方法及其在醫藥上的應用 - Google Patents
含氮雜環類化合物、其製備方法及其在醫藥上的應用 Download PDFInfo
- Publication number
- TW202313630A TW202313630A TW111119308A TW111119308A TW202313630A TW 202313630 A TW202313630 A TW 202313630A TW 111119308 A TW111119308 A TW 111119308A TW 111119308 A TW111119308 A TW 111119308A TW 202313630 A TW202313630 A TW 202313630A
- Authority
- TW
- Taiwan
- Prior art keywords
- general formula
- pharmaceutically acceptable
- alkyl
- acceptable salt
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110565410.0 | 2021-05-24 | ||
| CN202110565410 | 2021-05-24 | ||
| CN202110694022 | 2021-06-22 | ||
| CN202110694022.2 | 2021-06-22 | ||
| CN202110856289 | 2021-07-28 | ||
| CN202110856289.7 | 2021-07-28 | ||
| CN202210198679 | 2022-03-02 | ||
| CN202210198679.4 | 2022-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202313630A true TW202313630A (zh) | 2023-04-01 |
Family
ID=84229501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111119308A TW202313630A (zh) | 2021-05-24 | 2022-05-24 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240287094A1 (https=) |
| EP (1) | EP4349836A4 (https=) |
| JP (1) | JP2024519188A (https=) |
| KR (1) | KR20240012437A (https=) |
| CN (1) | CN117177971A (https=) |
| AU (1) | AU2022280845A1 (https=) |
| BR (1) | BR112023022496A2 (https=) |
| CA (1) | CA3219858A1 (https=) |
| MX (1) | MX2023013890A (https=) |
| TW (1) | TW202313630A (https=) |
| WO (1) | WO2022247816A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| WO2024041643A1 (zh) * | 2022-08-25 | 2024-02-29 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| CN120035596A (zh) * | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| AU2024286996A1 (en) | 2023-06-08 | 2026-01-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preparation method for formamide compounds |
| CN120677162A (zh) * | 2023-06-13 | 2025-09-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4138564A (en) | 1977-08-03 | 1979-02-06 | American Home Products Corporation | Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| US8299256B2 (en) | 2007-03-08 | 2012-10-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| US8404713B2 (en) | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| TWI693218B (zh) | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| JP7469304B2 (ja) * | 2018-11-16 | 2024-04-16 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐａｒｐインヒビタを含む医薬組成物 |
| MX2022000711A (es) * | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| CN116018132A (zh) | 2020-06-24 | 2023-04-25 | Itf研究制药有限公司 | 软明胶胶囊 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CN119110801A (zh) * | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
-
2022
- 2022-05-24 EP EP22810541.7A patent/EP4349836A4/en active Pending
- 2022-05-24 AU AU2022280845A patent/AU2022280845A1/en active Pending
- 2022-05-24 MX MX2023013890A patent/MX2023013890A/es unknown
- 2022-05-24 US US18/562,127 patent/US20240287094A1/en active Pending
- 2022-05-24 WO PCT/CN2022/094612 patent/WO2022247816A1/zh not_active Ceased
- 2022-05-24 TW TW111119308A patent/TW202313630A/zh unknown
- 2022-05-24 BR BR112023022496A patent/BR112023022496A2/pt unknown
- 2022-05-24 KR KR1020237042926A patent/KR20240012437A/ko active Pending
- 2022-05-24 CA CA3219858A patent/CA3219858A1/en active Pending
- 2022-05-24 JP JP2024515728A patent/JP2024519188A/ja active Pending
- 2022-05-24 CN CN202280027629.8A patent/CN117177971A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3219858A1 (en) | 2022-12-01 |
| BR112023022496A2 (pt) | 2024-01-16 |
| EP4349836A1 (en) | 2024-04-10 |
| US20240287094A1 (en) | 2024-08-29 |
| EP4349836A4 (en) | 2024-10-30 |
| JP2024519188A (ja) | 2024-05-08 |
| AU2022280845A1 (en) | 2023-12-14 |
| CN117177971A (zh) | 2023-12-05 |
| WO2022247816A1 (zh) | 2022-12-01 |
| KR20240012437A (ko) | 2024-01-29 |
| MX2023013890A (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202337890A (zh) | 橋環類化合物、其製備方法及其在醫藥上的應用 | |
| WO2024022444A1 (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| TW202313630A (zh) | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 | |
| TW202317587A (zh) | 稠合四環類化合物、其製備方法及其在醫藥上的應用 | |
| TW202325298A (zh) | 含氮的四環化合物、其製備方法及其在醫藥上的應用 | |
| CN115368383A (zh) | 稠合含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| TW202214639A (zh) | 吡啶酮并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
| CN114163454A (zh) | 含吡啶多环类衍生物抑制剂、其制备方法和应用 | |
| WO2021249475A1 (zh) | 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用 | |
| CN115403595A (zh) | 含氮杂环类化合物、其制备方法及其在医药上的应用 | |
| WO2021098811A1 (zh) | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| CN115594695A (zh) | 大环类化合物、其制备方法及其在医药上的应用 | |
| WO2024046420A1 (zh) | 稠合二环类化合物、其制备方法及其在医药上的应用 | |
| WO2024041643A1 (zh) | 稠合三环类化合物、其制备方法及其在医药上的应用 | |
| TW202246260A (zh) | 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用 | |
| CN113912608B (zh) | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 | |
| CN116640154A (zh) | 多环化合物、其制备方法及其在医药上的应用 | |
| CN113004303A (zh) | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 | |
| EA051431B1 (ru) | Азотсодержащее гетероциклическое соединение, способ его получения и его применение в качестве ингибитора parp1 | |
| TW202345852A (zh) | 稠雜環類化合物、其製備方法及其在醫藥上的應用 | |
| WO2021143821A1 (zh) | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| CN114907406A (zh) | 嘧啶衍生物、其制备方法及其在医药上的应用 | |
| TW202241862A (zh) | 二甲醯胺類化合物、其製備方法及其在醫藥上的應用 | |
| TW202241872A (zh) | 稠雜環基取代的環己二醯亞胺衍生物、其製備方法及其在醫藥上的應用 | |
| TW202229281A (zh) | 嘌呤酮類化合物、其製備方法及其在醫藥上的應用 |